Moderna’s COVID-19 vaccine phase 2/3 pediatric trial underway
Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial.
The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…